StockFin.ai Try Free →

Indoco Remedies Limited (INDOCO)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 16 June 2026

₹239.57 ↓ 15.51% (1Y)

🎯 Key Takeaways

Indoco Remedies Limited is undergoing a strategic transformation, divesting its non-core ophthalmic division to sharpen focus on higher-growth therapeutic areas while navigating a challenging financial trajectory marked by declining profitability and negative earnings trends..
Revenue declined 5.1% QoQ to ₹411 in Q3FY25.
⚠️ The ophthalmic division, while contributing only 3.2% of revenue, may have provided stable cash flows, and its exit could accelerate revenue decline i

Market Cap

₹2,076

P/E Ratio

-142.3

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About INDOCO 📊 Interactive Charts

📖 The Story

Indoco Remedies Limited is undergoing a strategic transformation, divesting its non-core ophthalmic division to sharpen focus on higher-growth therapeutic areas while navigating a challenging financial trajectory marked by declining profitability and negative earnings trends.

📰 What's Happening

In April 2026, the company approved the transfer of its ophthalmic division to Sunways India Private Limited for ₹110 crores, representing 3.2% of standalone revenue in FY2025. This divestment is part of a broader realignment to prioritize core therapeutic segments with stronger growth potential. The transaction, valued at a fixed amount and subject to regulatory approvals, is expected to close within three months. Management emphasized that the sale would enhance strategic focus without disclosing dilution or financial impact details. Prior to this, an earnings call was scheduled for May 7, 2026, to discuss audited standalone and consolidated results for Q4FY25 and FY2025, reflecting ongoing efforts to maintain investor engagement amid restructuring.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	428	427	482	459	450	431	433	411
Operating Profit	65	62	76	57	71	49	42	14
OPM %	15.1%	14.3%	14.8%	13.7%	10.9%	11.1%	9.3%	2.9%
Net Profit	26	24	35	16	22	2	-10	-28
EPS	₹2.80	₹2.62	₹3.82	₹1.69	₹2.39	₹0.20	₹-1.09	₹-3.08

The company's quarterly revenue has shown a consistent downward trend, declining from ₹482 crores in Q2FY24 to ₹411 crores in Q3FY25, with operating profit margin compressing from 14.8% to 2.9% over the same period. Net profit has swung from a healthy ₹35 crores in Q2FY24 to a loss of ₹28 crores in Q3FY25, indicating significant earnings deterioration. This decline coincides with the strategic divestment of the ophthalmic business, which contributed a small but stable portion of revenue, suggesting broader operational pressures or market headwinds are exacerbating the downturn.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance in the reviewed filings beyond acknowledging the expected closure of the ophthalmic divestment within three months. The focus remains on sharpening the portfolio and concentrating on core therapeutic areas with stronger growth potential, though no specific revenue or margin targets were communicated. The absence of detailed outlook reflects a transitional phase, with strategic clarity likely to emerge post-transaction completion.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. The ophthalmic division, while contributing only 3.2% of revenue, may have provided stable cash flows, and its exit could accelerate revenue decline if replacement growth is not achieved. 2. Persistent margin compression and declining profitability raise concerns about operational efficiency and cost management, particularly as revenue trends weaken. 3. The lack of disclosed financial impact from the divestment introduces uncertainty around capital allocation and whether proceeds will be reinvested or used for deleveraging.

📋 Recent Filings

🧠 Analyst's Read

Indoco Remedies is in a pivotal transitional phase, balancing portfolio simplification through asset divestment against declining operational performance. Investors should monitor the closure of the ophthalmic sale, the utilization of proceeds, and the trajectory of core business performance in upcoming quarters to assess whether the strategic shift can reverse the current earnings and margin downward trend.

Based on filing content and financial data. Not a recommendation.

✨ Deep Dive with AI on INDOCO

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-06-16.